Almost half of Singapore’s 5.7 million people have received at least one dose of Pfizer-BioNTech and Moderna vaccines.
In clinical trials, both have showed success rates of much over 90% against symptomatic illness, compared to Sinovac’s 51%.
More than 350 medical personnel in neighboring Indonesia have contracted COVID-19 despite being vaccinated with Sinovac, and dozens have been hospitalized, raising worries about the vaccine’s efficacy against more infectious strains.
To elicit an immune response, the Sinovac vaccine uses an inactivated or dead virus that cannot multiply in human cells.
Several social media comments have appeared in recent weeks claiming that inactivated viral COVID-19 vaccinations, such as Sinovac’s, give better protection against variations than mRNA vaccines. mRNA vaccines are said to be less safe in other messaging on platforms.
Authorities have dismissed these accusations, claiming that they are both safe and effective.